Bank of America Corp DE raised its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 34.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 352,841 shares of the specialty pharmaceutical company’s stock after purchasing an additional 89,984 shares during the quarter. Bank of America Corp DE’s holdings in Jazz Pharmaceuticals were worth $38,933,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Balentine LLC acquired a new position in Jazz Pharmaceuticals during the first quarter worth approximately $51,000. Bartlett & Co. LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter worth approximately $55,000. Northwestern Mutual Wealth Management Co. grew its stake in Jazz Pharmaceuticals by 1,571.1% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 752 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 707 shares during the period. Tower Research Capital LLC TRC grew its stake in Jazz Pharmaceuticals by 8,176.2% during the first quarter. Tower Research Capital LLC TRC now owns 1,738 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 1,717 shares during the period. Finally, Asahi Life Asset Management CO. LTD. purchased a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $193,000. 92.82% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on JAZZ. Wolfe Research upgraded shares of Jazz Pharmaceuticals from a “peer perform” rating to an “outperform” rating in a research note on Tuesday, July 28th. Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $165.00 to $167.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Oppenheimer began coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, July 30th. They set an “outperform” rating for the company. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, August 20th. Finally, Wells Fargo & Company upped their target price on shares of Jazz Pharmaceuticals from $150.00 to $171.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $161.81.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $134.90, for a total transaction of $67,450.00. Following the transaction, the chief executive officer now directly owns 336,680 shares in the company, valued at approximately $45,418,132. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 3,863 shares of company stock worth $503,644 over the last quarter. 4.60% of the stock is currently owned by insiders.

NASDAQ JAZZ opened at $141.50 on Wednesday. Jazz Pharmaceuticals PLC has a 12 month low of $86.88 and a 12 month high of $154.24. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.62 and a quick ratio of 5.39. The company has a market capitalization of $7.85 billion, a price-to-earnings ratio of 61.26, a price-to-earnings-growth ratio of 1.39 and a beta of 1.26. The company’s fifty day moving average price is $126.00 and its two-hundred day moving average price is $113.72.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.60. Jazz Pharmaceuticals had a net margin of 6.01% and a return on equity of 20.47%. The firm had revenue of $562.44 million for the quarter, compared to the consensus estimate of $503.19 million. During the same period in the prior year, the firm posted $4.05 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: What does a dividend yield signify to investors?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.